Acutus Medical (NASDAQ:AFIB) versus InfuSystem (NYSE:INFU) Head to Head Review

Acutus Medical (NASDAQ:AFIB) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Acutus Medical and InfuSystem”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acutus Medical	$7.16 million	0.22	-$81.66 million	N/A	N/A
InfuSystem	$134.86 million	0.94	$870,000.00	$0.10	60.60

InfuSystem has higher revenue and earnings than Acutus Medical.

Profitability

This table compares Acutus Medical and InfuSystem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acutus Medical	-272.74%	-311.64%	-11.57%
InfuSystem	1.12%	2.78%	1.41%

Analyst Ratings

This is a breakdown of current ratings for Acutus Medical and InfuSystem, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acutus Medical	0	0	0	0	0.00
InfuSystem	0	0	0	3	4.00

InfuSystem has a consensus price target of $13.00, indicating a potential upside of 114.52%. Given InfuSystem’s stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than Acutus Medical.

Institutional & Insider Ownership

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 10.2% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Acutus Medical has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Summary

InfuSystem beats Acutus Medical on 12 of the 12 factors compared between the two stocks.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.